Jared Gollob - Mar 1, 2024 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Medical Officer
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Mar 1, 2024
Transactions value $
-$139,967
Form type
4
Date filed
3/4/2024, 06:21 PM
Previous filing
Feb 29, 2024
Next filing
Jul 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Award $0 +24.4K +32.63% $0.00 99.1K Mar 1, 2024 Direct F1
transaction KYMR Common Stock Sale -$83.7K -2.02K -2.04% $41.41 97.1K Mar 4, 2024 Direct F2, F3
transaction KYMR Common Stock Sale -$46.9K -1.11K -1.14% $42.39 96K Mar 4, 2024 Direct F2, F4
transaction KYMR Common Stock Sale -$9.34K -216 -0.23% $43.26 95.7K Mar 4, 2024 Direct F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +146K $0.00 146K Mar 1, 2024 Common Stock 146K $43.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.
F2 Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.